FY2029 Earnings Forecast for TYRA Issued By Wedbush

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Analysts at Wedbush issued their FY2029 EPS estimates for Tyra Biosciences in a research note issued on Friday, March 28th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.91) for the year. Wedbush has a “Outperform” rating and a $30.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share.

TYRA has been the subject of several other research reports. UBS Group assumed coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $9.77 on Monday. Tyra Biosciences has a 12-month low of $9.49 and a 12-month high of $29.60. The firm has a market capitalization of $494.39 million, a price-to-earnings ratio of -6.07 and a beta of 1.09. The business has a 50 day simple moving average of $12.46 and a 200 day simple moving average of $16.30.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total value of $65,325.48. Following the transaction, the director now owns 3,707,420 shares of the company’s stock, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Tyra Biosciences

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP raised its holdings in Tyra Biosciences by 4.4% during the 4th quarter. Wellington Management Group LLP now owns 94,859 shares of the company’s stock worth $1,319,000 after buying an additional 4,034 shares during the period. Polar Asset Management Partners Inc. raised its holdings in shares of Tyra Biosciences by 26.1% during the fourth quarter. Polar Asset Management Partners Inc. now owns 111,107 shares of the company’s stock valued at $1,544,000 after acquiring an additional 23,007 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Tyra Biosciences by 41.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,635 shares of the company’s stock valued at $495,000 after acquiring an additional 10,426 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $13,761,000. Finally, Squarepoint Ops LLC acquired a new position in Tyra Biosciences in the 4th quarter worth approximately $253,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.